Dose Conversion: Serdexmethylphenidate 39.2mg to Dexmethylphenidate XR
Serdexmethylphenidate 39.2mg/dexmethylphenidate 7.8mg (SDX/d-MPH) is approximately equivalent to 30mg of dexmethylphenidate extended-release.
Pharmacokinetic Basis for Conversion
The FDA label for serdexmethylphenidate (AZSTARYS) explicitly states that each capsule contains a fixed molar ratio of 30% immediate-release dexmethylphenidate and 70% serdexmethylphenidate (a prodrug that converts to dexmethylphenidate) 1. The combined molar dose of the 39.2mg/7.8mg formulation is equivalent to 30mg dexmethylphenidate hydrochloride 1.
However, direct milligram-per-milligram substitution is not appropriate because these formulations have fundamentally different pharmacokinetic profiles 1. When comparing SDX/d-MPH 52.3mg/10.4mg to dexmethylphenidate XR 40mg under fasted conditions:
- SDX/d-MPH produced a mean Cmax of 14.0 ng/mL and AUC of 186 hour*ng/mL
- Dexmethylphenidate XR 40mg produced a mean Cmax of 28.2 ng/mL and AUC of 248 hour*ng/mL 1
This demonstrates that SDX/d-MPH delivers approximately 75% of the total exposure (AUC) and 50% of the peak concentration compared to dexmethylphenidate XR at equivalent molar doses.
Clinical Conversion Approach
When switching from SDX/d-MPH 39.2mg/7.8mg, start with dexmethylphenidate XR 30mg and titrate based on clinical response 1. The FDA label explicitly warns: "Do not substitute AZSTARYS for other methylphenidate products on a milligram-per-milligram basis because these products have different pharmacokinetic profiles" 1.
Key Pharmacokinetic Differences to Consider:
- Duration of effect: SDX/d-MPH provides extended coverage (demonstrated efficacy 0.5-13 hours post-dose in laboratory classroom studies) 2, while standard dexmethylphenidate XR typically provides 8-12 hours of coverage
- Peak timing: SDX/d-MPH reaches Tmax at approximately 2 hours, with the prodrug component extending release 1
- Exposure pattern: SDX/d-MPH delivers lower peak concentrations but more sustained exposure compared to dexmethylphenidate XR 1
Titration After Conversion
After initiating dexmethylphenidate XR 30mg, monitor for:
- Inadequate symptom control: May require uptitration to 35-40mg based on the higher AUC typically seen with dexmethylphenidate XR formulations
- Excessive side effects: May require downtitration to 20-25mg, particularly if the patient tolerated the lower peak concentrations of SDX/d-MPH well
- Duration of coverage: Patients may report earlier symptom return in the evening compared to SDX/d-MPH due to different release kinetics
The conversion should be individualized based on symptom response, with weekly dose adjustments of 5-10mg as needed 3. Maximum recommended daily dose for dexmethylphenidate is 40mg 3.
Common Pitfall to Avoid:
Do not assume equivalent efficacy at the molar equivalent dose. The 25% reduction in total exposure (AUC) with SDX/d-MPH means some patients may require higher doses of dexmethylphenidate XR (35-40mg) to achieve comparable symptom control, while others may experience more side effects from the higher peak concentrations and require lower doses (20-25mg).